Plasma ctDNA testing for FGFR alterations in metastatic urothelial carcinoma shows high concordance with tissue testing and identifies additional patients with actionable alterations. Here, the authors show that clinical uptake of ctDNA FGFR testing can be combined with tissue-based approaches.
- David C. Müller
- Andrew J. Murtha
- Bernhard J. Eigl
